OBJECTIVES: In patients with acquired valvar disease, morbidity and mortality rates after tricuspid valve replacement (TVR) are high. However, in adult patients with congenital heart disease, though data concerning outcome after TVR are scarce, even poorer results are suggested in patients with Ebstein anomaly. To investigate the applicability of these results to a broader array of congenital heart disease patients, we report the long-term follow-up of prosthesis-related complications, including re-replacement of patients with a tricuspid valve prosthesis and congenital heart disease.
INTRODUCTION
Tricuspid valve dysfunction, particularly regurgitation, is common and usually the result of acquired valvar disease. A small proportion of tricuspid valve dysfunctions are caused by congenital heart defects (CHD), be it structural (e.g. Morbus Ebstein) or functional (e.g. secondary to dilatation of the right ventricle and/or pulmonary hypertension) [1] , and may need surgery. In general, indications for tricuspid valve surgery include: deterioration of functional capacity (NYHA ≥III), right-sided heart failure (despite pharmaceutical intervention), embolisms or recurring supraventricular arrhythmias [2] . Tricuspid valve repair has evolved over the years and remains the preferred technique, but replacement of a dysfunctional tricuspid valve with a prosthesis is sometimes inevitable [3] . In patients with acquired tricuspid valve disease, tricuspid valve replacement (TVR) remains a major surgical intervention with a considerable reported risk of mortality (7-22%), and a high incidence of prosthesis-related complications (14-34%), which results in a high number of reoperations (10-22%) during a followup of 5-9 years [4] [5] [6] [7] . Data on TVR in patients with CHD are scarce, but seem to report even poorer results. This is demonstrated by reports on patients with Ebstein anomaly with a reoperation rate of 18-26% in bioprostheses and 30% in mechanical prostheses within 10 years [8, 9] . Whether this holds true for a mixed population of CHD patients with a tricuspid prosthesis is uncertain.
Our objective is therefore to report the follow-up ( prosthesisrelated complications including re-replacement) of CHD patients with TVR derived from the multicentre Dutch Congenital Corvitia (CONCOR) registry [10] and to relate the outcome to baseline prosthetic and patient characteristics, including prosthesis-patient mismatch (PPM).
PATIENTS AND METHODS

Patient inclusion
Patients were selected from the Dutch PROSTAVA study (PROSTheses in Adult congenital heart VAlve disease) [11] that includes adult CHD patients with prosthetic heart valves (n = 720). This study is currently prospectively investigating the impact of prosthetic valves on quality of life and functional outcomes. A second objective is the retrospective investigation of the rate of prosthetic valve-related complications. For the PROSTAVA study, we recruited patients from the Dutch national CONCOR registry [10] initiated in 2001, which intends to register all adults with CHD and now comprises a study population of >14 000 patients. All patients gave written informed consent for registration in CONCOR. The current study is a retrospective analysis of PROSTAVA study patients with a prosthetic valve in the tricuspid position. For this study, we recruited patients from four university medical centres. Patients with a surgically or congenitally corrected transposition of the great arteries were excluded as the morphologically tricuspid valve functions as the systemic atrioventricular valve and is therefore subject to systemic ventricular physiology. Data were collected from the date of the patients' first TVR up to March 2012 by reviewing patient records. The Ethical Committee of the University Medical Centre Groningen approved this retrospective study and waived informed consent.
Tricuspid valve replacement procedure
Traditional median sternotomy and central aortobicaval cannulation were performed in all but one procedure, where a third successive tricuspid prosthesis was implanted using a transcatheter procedure. When no interatrial shunt existed, the operation was performed on a beating heart. The most fitting prosthesis was selected by using standard valve sizers. The type of prosthesis (mechanical or biological) was chosen by the cardiosurgical multidisciplinary team. Patients with a mechanical prosthesis received anticoagulation therapy (international normalized ratio [INR] 3.0-4.0) postoperatively, and the INR was monitored in an outpatient lab, clinic or at home (self-management).
Endpoints
Primary endpoints comprised valve-related complications, not necessarily followed by a re-TVR, and were scored by two researchers (Y.J.v.S. and P.G.P.). These complications are defined in the guidelines for reporting mortality and morbidity after cardiac valve interventions [12] and include structural valve deterioration, non-structural valve dysfunction, valve thrombosis, embolism, severe haemorrhaging and endocarditis.
Secondary endpoints included early and late death, and early morbidity (including cardiac tamponade or excessive bleeding that needed intervention, sepsis, renal failure requiring dialysis and cerebrovascular accidents within 30 days). Mortality within and after 30 days was reported as cardiac valve-related, cardiac non-valve-related or other. However, patients who died before CONCOR was initiated remain unidentified and are not included in this study. We therefore only report the observed mortality of the CONCOR registered patients in this study in a descriptive manner.
Prosthesis-patient mismatch
In vitro effective orifice areas (EOAs) of prostheses at implantation were extracted from the literature if available [13, 14] and indexed (iEOA) using the body surface area (BSA) as retrieved from patient records at the time of the TVR. As there are no published cut-off values for tricuspid valve PPM, the cut-off values for mitral PPM were adjusted for the tricuspid valve using a calculated ratio of normal mitral EOA vs tricuspid valve EOA. Of note, as heart valves are not perfect geometric shapes, calculations from dimensions represent an approximation. In adults, the average tricuspid valve diameter is 18% larger than their mitral valve, which means that the tricuspid EOA would be 40% larger than that of the mitral valve [15] . Applying this ratio to accepted mitral valve PPM thresholds (PPM = iEOA < 
Statistical analysis
Statistical analyses were performed using the statistical software package SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA). Continuous data were tested for normality and are presented as mean ± standard deviation, as median with interquartile range (IQR), or as proportions for dichotomous variables. The χ 2 test or Fisher's exact test was used to compare the groups with categorical variables, Student's unpaired t-test for the analysis of normally distributed continuous variables or Mann-Whitney U-test for not normally distributed continuous variables. Follow-up was calculated from the date of surgery to either the time of data collection, death or the date of valve-related event for 'event-free survival' and illustrated using Kaplan-Meier graphs, including confidence intervals (CIs), where the equality was tested using log rank. A twosided P-value of <0.05 was considered statistically significant. Event incidence is reported as the percentage of patients experiencing the event per year (xx % patient/year) in a population at risk.
RESULTS
Baseline data at initial tricuspid valve replacement
We identified 37 CHD patients with a tricuspid valve prosthesis. After exclusion of TVRs in the systemic circulation, 20 patients remained with their initial TVR implanted between September 1977 and February 2012. Baseline characteristics are outlined in Table 1 . The patients who received a bioprosthesis (n = 10) were slightly younger at the time of initial TVR when compared with the group of patients who received a mechanical prosthesis (n = 10), median 16.2 (IQR 13.2-28.2) vs 36.4 (IQR 14.0-47.0) years, (P = 0.28). The mean follow-up after the first TVR in all patients was 14.0 ± 9.3 years. The most frequent indications for initial replacement of the tricuspid valve were tricuspid regurgitation (n = 17) based on structural valve dysfunction (n = 16) or functional valve dysfunction caused by annular dilatation (n = 1). The prosthesis types and sizes that were used for the TVR are listed in Table 2 .
Ebstein anomaly
The most frequent diagnosis in our population was Ebstein anomaly (n = 11) with various degrees of downward displacement of the tricuspid valve (leaflets) into the right ventricle. Tricuspid valve regurgitation was the reason for all TVRs in Ebstein patients compared with 66% in non-Ebstein patients. The age of Ebstein patients differed non-significantly at the first TVR compared with the non-Ebstein patients, median 16.9 years (IQR 14.0-39.4) vs 35.6 (IQR 12.4-49.2) years, (P = 0.66). Follow-up data of the Ebstein patients were similar to the non-Ebstein patients in terms of the duration of follow-up, incidence of early and late morbidity, incidence of early and late mortality and re-TVRs. The following results are therefore based on the whole group (n = 20).
Valve-related complications
Eleven (55%) patients experienced valve-related complications after their first TVR with comparable mean event-free survival times in biological (11.7 ± 9.9 years) and mechanical (9.7 ± 7.0 years) prostheses. There were 31 TVRs in 20 patients ( Table 2 ). The total 5-year and 10-year event-free survivals were 60 and 50% in the group of patients with bioprostheses and 86 and 78% in the group of patients with mechanical prostheses (Figs 1 and 2 ). The estimated median event-free intervals were 10.1 years (CI 0.6-19.6) in bioprostheses and 18.7 years (CI 8.2-29.1) in mechanical prostheses (P = 0.44). Seven (35%) patients were still event free after their first TVR.
Structural valve deterioration in biological prostheses as main complication
In this cohort, the incidence of structural valve deterioration caused by calcification in a biological prosthesis (eventually necessitating re-TVR) was 4.2% patient/year. Ebstein anomaly (n = 4), atrial septal defect (ASD) and pulmonary valve stenosis (n = 1), and VSD (n = 1) were the underlying defects. These 6 patients had a mean age of 12.9 ± 1.7 (range 5.1-16.9) years at implantation. The prosthesis had to be replaced after an average interval of 11.6 ± 9.2 (range 3.0-26.8) years. Overall, the proportion of bioprostheses suffering from severe structural valve deterioration were 17% after 5 years, 29% after 10 years and 55% after 15 years. One patient died before the re-replacement was initiated. No valve thrombosis occurred in patients with a bioprosthesis.
Thrombosis in mechanical prostheses as main complication
The incidence of valve thrombosis in a mechanical prosthesis was 2.7% patient/year. In 3 patients, thrombosis of the initial mechanical valve necessitated a re-TVR after intervals of 2.6, 13.0 and 18.9 years, respectively. A fourth patient suffered from fatal thrombosis of her second prosthesis 25 years after implantation. Underlying defects were Ebstein anomaly (n = 1), ASD and pulmonary valve stenosis (n = 1), Marfan (n = 1) and double outlet right ventricle (n = 1). Of note, upon hospital admission, all 4 patients were on vitamin K antagonists with a suboptimal INR (<2.0). In 3 patients, thrombolytic agents were administered, but yielded insufficient results. In all cases, the diagnosis was made by transthoracic echocardiography. The reasons for echocardiography were sudden weight gain and oedema in 3 patients, with cessation of valvar sounds in 1 of them and routine check-up in 1 other. None of the patients with prosthetic valve thrombosis had atrial fibrillation or other additional risk factors that necessitated anticoagulation. We found no structural valve deterioration in patients with a mechanical prosthesis.
Tricuspid valve re-replacement
Ten (50%) patients needed a re-replacement of the tricuspid valve prosthesis (Table 2 ), but 1 died before the re-replacement was initiated. Reasons for re-TVR in patients with biological prostheses were structural valve deterioration (n = 6) caused by calcification. In mechanical prostheses, the reasons for re-TVR were valve thrombosis (n = 3) or endocarditis (n = 1). The rate of replacement was comparable between bioprostheses (60%) and mechanical prostheses (40%) during our follow-up. Only 1 patient needed a re-re-TVR 8 years after a second bioprosthesis due to structural deterioration. The cardiosurgical team decided to implant a percutaneous bioprosthesis in the tricuspid position because of the high risk of an open procedure.
Prosthesis-patient mismatch
Eleven (36%) prostheses were categorized as PPM at implantation, 1 (4%) as severe PPM and 13 (42%) as no PPM. We missed six iEOAs (19%) because of missing BSA (n = 1), or because the prostheses are no longer in production (Medtronic Intact® bioprostheses and Duromedics® mechanical prostheses), and the data could not be provided by the manufacturers or found in the literature (n = 5; Table 2 ). The incidence of valve-related events was comparable in prostheses with (severe) PPM (45%) and without PPM (54%). However, looking at events within 20 years after implantation, the median duration of event-free survival was significantly shorter in patients with (severe) PPM (1.0 years; IQR 0.01-2.6) compared with those without PPM (8.0 years; IQR 5.1-12.3; P = 0.02).
Mortality and early morbidity
The 30-day morbidity included an ischaemic cerebrovascular accident (n = 1), renal failure that required short-term dialysis (n = 2), sepsis (n = 1) and re-exploration due to persistent bleeding (n = 1). The majority of patients (n = 15) were registered in CONCOR after their first TVR, which prohibits valid calculation of time-related mortality proportions. One 49-year old patient with a corrected Tetralogy of Fallot in NYHA Class IV died within 30 days of the operation. She developed irreversible right ventricular failure following a Carpentier Edwards® bovine pericardial TVR. We observed 2 late deaths in our cohort after the initial TVR: a 59-year old atrioventricular septal defect patient with a Björk-Shiley® mechanical prosthesis died following left-sided heart failure 23 years after implantation of left-and right-sided atrioventricular valves, and one 33-year old Ebstein patient with a Medtronic® porcine aortic bioprosthesis died following right-sided cardiac failure due to stenotic deterioration of the prosthesis 18.0 years after implantation. After a second TVR, there was 1 late death in a 27-year old patient, following mechanical valve thrombosis and endocarditis that triggered cardiac failure and death 12 years after implantation. In total, after 2001, 4 patients died during a total follow-up of 291 patient-years.
DISCUSSION
This study solely reports the long-term follow-up of patients with CHD and a tricuspid valve prosthesis, which is rare in the literature. The only large series of patients with tricuspid valve prostheses are that of the Mayo Clinic who, due to a nationwide referral pattern, succeeded in collecting a huge amount of data from which a number of publications stem [8, 9] . Half of our patients suffered long-term valve-related complications after their first prosthesis during a mean follow-up of 14 years, which is higher compared with studies almost exclusively on patients with acquired valvar disease with a shorter mean follow-up time (6-9 years), reporting long-term TVR complication rates of 10-34% [1, [4] [5] [6] [7] . Our complication rates are also higher than those (10-26%) in the study from the Mayo Clinic reporting on 176 Ebstein patients during a follow-up of 10 years [8] . However, they obtained their data from a questionnaire that was sent to longterm survivors with a return result representing less than half of their original population, which leaves open the possibility that their outcome is positively biased. Almost all of our patients with a prosthesis-related complication required a re-TVR. The indications for reoperation were similar to previous studies on prosthetic tricuspid valves: valve thrombosis in mechanical valve prostheses and structural valve deterioration in bioprosthetic valves [1, 4, [16] [17] [18] .
Structural deterioration of biological prostheses
We report a higher incidence of bioprosthetic valve deterioration in our patients (4.2% patient/year) than Rizzoli et al. [19] in a meta-analysis of 11 studies reporting almost exclusively on acquired tricuspid valve disease (1.7% patient/year [IQR 0.4-2.3]). This could be explained by the younger age of our patients at implantation (12.9 ± 1.7 years), which is known to be a risk factor for structural biological valve deterioration [3, 8] . For that reason, young age is a relative contraindication for the use of a bioprosthesis. However, in case of severe comorbidity, limited life expectancy, or contraindication for or compliance problems with oral anticoagulation, a bioprosthesis must be considered [2] . Contemplating pregnancy is also considered an indication for a bioprosthesis as mechanical valves increase the risk of valve thrombosis during pregnancy despite strict compliance with oral or heparin anticoagulation. Additionally, anticoagulation therapy increases the risk of haemorrhagic complications and of offspring complications such as embryopathy [20] . Finally, in patients with a bioprosthetic valve, a percutaneous tricuspid valve implantation could become optional in case of valve failure. Of course, valve-in-valve implantation enlarges the EOA in stenotic degenerative valves, but will always be limited by the maximum internal diameter of the mounting ring of the degenerated bioprosthesis inside the native annulus. One should therefore consider that, by definition, the maximum orifice area will be smaller in a valve-in-valve implantation compared with a complete replacement of a stenotic bioprosthesis, and may therefore facilitate PPM. The risk of inducing PPM should be acknowledged when choosing between surgical or percutaneous TVRs.
Thrombosis in mechanical prostheses
The thromboembolic risk in right-sided mechanical valve prostheses is higher than in left-sided prostheses. Whether this is due to lower levels of prostacyclin in systemic venous blood or because of a less-pronounced washing effect of the prosthetic hinges is still a matter of debate [21] . It is known that adequate anticoagulation reduces the annual incidence of prosthetic thrombosis of left-sided valves. Adequate compliance with anticoagulation therapy is therefore extremely important, likely even more so in patients with right-sided prostheses. The risk of valve thrombosis, as well as its consequences, is unfortunately sometimes underappreciated by both doctors and patients. In this small study, the incidence of valve thrombosis was 2.7% patient/year, which is considerably higher than the median incidence of 1.3% patient/year (IQR 0.5-2.2) reported by Rizzoli et al. [19] . The high rate of tricuspid valve thrombosis in our young population seemed to be entirely related to inadequate anticoagulation. Young people are thought to be less compliant with anticoagulation therapy because of life phase, lifestyle and the tendency to deny the potential implications of poor compliance. As thrombosis in biological tricuspid prostheses is very rare [7] , the majority of thrombotic mechanical valves were replaced by a bioprosthesis to minimize the risk of recurrence.
Re-replacement of the tricuspid valve
We found an overall redo rate of 50% during a mean follow-up of 14 years, which is similar to other studies on CHD [3, 8, 22] , but is higher than the reoperation rate of 10-22% reported for patients with acquired tricuspid valve disease during a follow-up of 7-9 years [5, 7] . Obviously, this is a direct result of the higher complication rate that we found in our CHD population as discussed above, and the longer follow-up time.
In our cohort, the mean incidence of reoperation due to degeneration of the bioprosthesis was similar to that of reoperation due to thrombosis of mechanical prostheses on the long term, and comparable with other studies [19] . There seems to be an increased rate of early failure of bioprostheses compared with mechanical prostheses in this small population.
Prosthesis-patient mismatch
The in vitro EOA data of prosthetic valves are nearly impossible to retrieve. According to the International Standard (ISO) on cardiovascular implants and cardiac valve prostheses, the manufacturers are required to deliver prostheses with a minimum hydrodynamic performance level as tested according to the ISO preset guidelines. These minimum performance requirements (including the EOA) must be indicated in the clinical investigation report, but are not all required to be stated on the label provided with the prosthesis. This hampers surgeons and researchers when comparing different valve types. Furthermore, the ISO document has only recently (2005) been improved to assist the surgeon in selecting the appropriate size prosthetic valve. Prostheses from before the ISO standardization may thus differ in size labelling.
As we were not able to obtain comprehensive data of in vitro EOAs, we used in vivo data from the literature where necessary to calculate iEOA. We expected the reoperation rate due to PPM to be high in this CHD population, but in vivo PPM due to somatic growth was never the direct reason for any re-TVR. However, we did find a suggestive negative relationship between having PPM and the time interval at which an event occurred that necessitated a re-TVR.
In all our TVRs, the mechanical prostheses that were used were designed for the replacement of systemic valves, usually the mitral valve. However, blood pressure and pressure gradients (ΔP) in the pulmonary circulation are much lower than in the systemic circulation. To maintain proper blood flow (Q) through the complete vascular system, the resistance (R) has to be lower in a lowpressure system compared with a high-pressure system (Ohm's law: Q = ΔP/R). Resistance is affected by viscous and inertial forces that are minimized by natural vascular dimensions that are optimal also during exercise. A theoretical range of normal optimal valve diameters needed for different levels of bodily activity can be calculated using the principles of minimal work as demonstrated by Sluysmans and Colan [23] . Using Poiseuille's law ½Q ¼ ðDP Â p Â r 2 Þ=8 Â h Â LÞ on heart valves, where the length of the valve (L) is negligible and the coefficient of viscosity (η) of blood is assumed to be equal in the whole cardiovascular system, flow is dependent on the radius (r) and thus on the EOA of the valve. So, in order to minimize energy dissipation in a lowerpressure system, the EOA of the valve has to be larger than in a high-pressure system, which is demonstrated by the normal tricuspid valve having a 40% larger area than the mitral valve [15] . However, to maintain the principle of minimal work, the valve area must not be too large as kinetic energy will then be lost. This is demonstrated by the pulmonary valve that is larger than the aortic valve [24] , but in a lesser degree than the atrioventricular valves, as it has to preserve the kinetic energy created by the right ventricle. Of course, Poiseuille's law has its limitations in the human body as our blood flow is not laminar, and the vascular system does not have a constant circular cross-section, but it can help illustrate certain dilemmas.
It is questionable whether the geometric orifice area is relevant in this study. It may well be that other elements in valve design have a greater impact on EOA, particularly in low-pressure circumstances. As the pressure propelling blood through the tricuspid valve is the lowest in the circulation, the native tricuspid valve is the largest. However, even in the large tricuspid annulus, various degrees of PPM (according to our theoretical definition) were observed in all prosthetic tricuspid valve size categories in this study. As the most fitting prosthesis is chosen according to the patient's annulus size, and oversizing is often not an option without compromising the right coronary artery, the valve design itself may have to be improved to increase the EOA in relation to body size. In addition, the largest tricuspid prostheses available have a labelled size of 33 mm, but in mechanical prostheses, only the sewing ring is enlarged compared with the 31 mm, not the EOA. As this study suggests that PPM may have a negative effect on event-free interval, we feel that prostheses with a larger ratio of EOA to annulus size may need to be designed for the tricuspid position.
Survival
Recent studies show an average 5-year survival of 73.1 ± 5.1% and an average 10-year survival of 57.2 ± 17.0%, following a TVR in acquired tricuspid valve disease [4-6, 18, 19, 25] . In patients with CHD, results are more favourable, as shown by studies on patients with Ebstein anomaly in whom 5-and 10-year survivals of 88-93 and 85-93%, respectively, are reported in bioprostheses, and 74 and 67%, respectively, in mechanical (mainly Starr-Edwards caged-ball) prostheses [8, 9] . This difference in survival between acquired and congenital TVRs might well be due to differences in age at implantation. Although our results seem encouraging, due to the nature of our cohort, direct comparison with current literature is invalid.
Strengths and limitations
This study is limited by the small number of patients and the heterogeneity of the cardiac anatomy, which limits the power of statistical analyses. To obtain acceptable numbers, this study covers a long period of time during which surgical techniques and intensive care have changed. Furthermore, the CONCOR database represents a survival cohort of adult patients registered from 2001 onwards, which limits our data on mortality and to a lesser extent also on morbidity due to mortality before registration.
Because heart valves are never perfect geometric shapes, the calculated ratio between mitral and tricuspid valve EOAs should be considered an approximation. The proposed cut-off value for PPM is a theoretical suggestion and should be validated in further clinical research. The number of EOAs was limited as certain valve types are no longer in production and no echocardiographic data were available in the literature.
Despite the limitations, our study is one of the few to report on late outcome solely in CHD patients with a prosthetic tricuspid valve.
CONCLUSION
This study shows a valve-related complication rate of 50% in CHD patients with a prosthetic tricuspid valve during a mean follow-up of 14 years. We report a higher incidence of structural valve deterioration of bioprostheses and a higher incidence of valve thrombosis in mechanical prostheses compared with the literature on acquired tricuspid valve disease. The median event-free interval is significantly shorter in patients with PPM. We emphasize that the choice of prosthesis with regard to size and design should be individualized and further investigated. To improve genuine prosthetic valve comparison, we advocate in vitro EOAs to be reported on the product label of all prosthetic heart valves.
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